As­traZeneca taps two more tar­gets from its AI part­ner, again in CKD and IPF

As­traZeneca is dou­bling down in chron­ic kid­ney dis­ease and id­io­path­ic pul­monary fi­bro­sis by se­lect­ing one tar­get for each of those via its AI-pow­ered part­ner. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER